This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Metanx® Study Published In The American Journal Of Pharmacy Benefits Indicates Treatment Lowers The Risk Of Hospitalization And Decreases Disease-Related Costs

NEW ORLEANS, Nov. 19, 2012 /PRNewswire/ -- PamLab L.L.C., developer and marketer of Metanx ®, announced today that a study published in The American Journal of Pharmacy Benefits demonstrates the effects of Metanx ® on commercially insured patients with Diabetic Peripheral Neuropathy (DPN). Patients in the Metanx ® group had lower risks of hospitalization and a reduction of disease related costs. The retrospective study, conducted by Rolin Wade RPh, MS from Cerner Research in Culver City, compared two well-matched groups of 814 patients with DPN; one of which was prescribed the medical food, Metanx ®. The study showcased the fact that the Metanx ® patient group had an average of $2,258 lower disease-related costs in 12 months of follow-up.

Diabetic peripheral neuropathy is caused by disruption in the natural metabolic processes in blood vessels and peripheral nerve tissues, a common complication of diabetes. People who have DPN have a higher incidence of diabetes-related conditions such as coronary artery disease, back pain, limb amputations, depression, hypertension, peripheral vascular disease, and limb infections, along with a need to typically manage pain when compared to patients who have diabetes without neuropathy.

In the study of commercially insured patients with DPN, the Metanx ® treated group had a lower all-cause hospitalization risk during the follow up period than the non-Metanx ® group. The study reports that Metanx ®, a medical food, may have a favorable clinical and cost benefit to DPN patients and should be considered when making treatment decisions. This study was conducted in a manner to ensure patient anonymity and the safeguarding of all medical data.

Commenting on the study publication, author Wade stated that, "This study supports previous findings that managing the underlying condition is vital in diabetes. One of the biggest health care challenges in the U.S. is diabetes, with peripheral neuropathy being a serious complication that can lead to infection, hospitalization and even amputation. I was pleased to be able to work with PamLab to conduct this study using one of the largest insurance claims databases in the U.S. to show that therapy with Metanx was associated with lower rates of hospitalization and overall treatment costs compared to matched controls."

About Medical Foods and Metanx ®As regulated by the FDA, medical foods are specially formulated to manage a specific disease or condition for which medical evaluation, based on recognized scientific principles, has established distinct nutritional requirements. All components of a medical food must have GRAS status (Generally Recognized as Safe) as designated by the FDA or independent review. 

Metanx ® is a medical food dispensed by prescription and indicated for the distinct nutritional requirements of patients with endothelial dysfunction who present with loss of protective sensation and neuropathic pain associated with diabetic neuropathy.  Metanx ® contains the active forms of folate and Vitamins B 12 and B 6 (L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate, respectively).  Metanx ® offers a nutritional benefit, needed by diabetics with peripheral neuropathy, by improving endothelial function and maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves.

About PamLab, L.L.C.PamLab, L.L.C., founded in 1957, is a fully integrated pharmaceutical company specializing in medical foods indicated for the nutritional support of specific disease states including diabetic neuropathy, depression and early memory loss.

About CernerCerner is contributing to the systemic change of health and care delivery. For more than 30 years Cerner has been executing its vision to make health care safer and more efficient. We started with the foundation of digitizing paper processes and now offer the most comprehensive array of information software, professional services, medical device integration, remote hosting and employer health and wellness services. Cerner systems are used by everyone from individual consumers, to single-doctor practices, hospitals, employers and entire countries. Taking what we've learned over more than three decades, Cerner is building on the knowledge that is in the system to support evidence-based clinical decisions, prevent medical errors and empower patients in their care.

Cerner® solutions are licensed by approximately 9,300 facilities around the world, including more than 2,650 hospitals; 3,750 physician practices; 40,000 physicians; 500 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 40 employer sites and 1,600 retail pharmacies.

Certain trademarks, service marks and logos (collectively, the "Marks") set forth herein are owned by Cerner Corporation and/or its subsidiaries in the United States and certain other countries throughout the world. All other non-Cerner Marks are the property of their respective owners. Nasdaq: CERN. For more information about Cerner, please visit  www.cerner.comTwitterFacebook and  YouTube.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs